High‐dose interleukin‐2 for the treatment of metastatic renal cell carcinoma

医学 肾细胞癌 内科学 比例危险模型 单变量分析 人口 逻辑回归 肿瘤科 癌症 多元分析 癌 外科 胃肠病学 环境卫生
作者
Jacob A. Klapper,Stephanie G. Downey,Franz Omar Smith,James Chih‐Hsin Yang,Marybeth S. Hughes,Udai S. Kammula,Richard Mark Sherry,Richard Eldon Royal,Seth M. Steinberg,Steven A. Rosenberg
出处
期刊:Cancer [Wiley]
卷期号:113 (2): 293-301 被引量:440
标识
DOI:10.1002/cncr.23552
摘要

BACKGROUND: The treatment of metastatic renal cell carcinoma (RCC) with high-dose interleukin-2 (HD IL-2) has resulted in durable tumor regression in a minority of patients. The current study presents the authors' 20-year experience administering this immunotherapeutic agent. METHODS: Patients with metastatic RCC (n = 259) were treated with HD IL-2 alone from January 13, 1986 through December 31, 2006 at the Surgery Branch of the National Cancer Institute. Potential predictive factors for response and survival, both pretreatment and treatment-related, were first subjected to univariate analysis and then to multivariate logistic regression or a Cox proportional hazards model. Finally, the authors investigated Memorial Sloan-Kettering Cancer Center (MSKCC) prognostic factors for survival to assess their predictive value in the patient population in the current study. RESULTS: A total of 23 patients experienced a complete response and 30 patients achieved a partial response, for an overall objective response rate of 20%. All partial responders had developed disease recurrence at the time of last follow-up, but only 4 complete responders had experienced disease recurrence by that time. Despite toxicities, only 2 patients developed treatment-related mortalities over this same time period. A higher baseline weight (P = .05) and MSKCC prognostic factors (P = .02) were found to be the variables most associated with response. For survival >4 years and overall survival, several pretreatment and treatment-related factors maintained significance, but none more so than response (P < .0001). CONCLUSIONS: HD IL-2 can induce complete tumor regression in a small number of patients, and many patients have experienced extended disease-free intervals. Given its relative safety, HD IL-2 should still be considered a first-line therapy in patients with metastatic RCC who have an overall good performance status.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
无极微光的应助被阿辉采纳,获得182
刚刚
我是老大的应助被Helium采纳,获得10
刚刚
sunnio完成签到,获得积分10
刚刚
刚刚
1秒前
领导范儿的应助被Jeannie采纳,获得10
1秒前
Doki完成签到,获得积分20
1秒前
激动的元瑶完成签到 ,获得积分10
1秒前
1秒前
甜美折耳根完成签到,获得积分10
1秒前
从容的映之完成签到,获得积分10
2秒前
cjk发布了新的文献求助10
2秒前
文静的笑槐完成签到,获得积分10
3秒前
lee发布了新的文献求助70
3秒前
3秒前
3秒前
3秒前
略略略爱完成签到,获得积分10
3秒前
uiii发布了新的文献求助10
3秒前
4秒前
初景发布了新的文献求助10
4秒前
幽默枫发布了新的文献求助10
4秒前
H_完成签到 ,获得积分10
4秒前
zhaung发布了新的文献求助10
4秒前
4秒前
wchwei123发布了新的文献求助10
4秒前
4秒前
wearelulu完成签到,获得积分10
5秒前
apricity199的应助被qww采纳,获得10
5秒前
黑心茶叶蛋完成签到,获得积分10
5秒前
Chengdi完成签到,获得积分10
6秒前
gzslwddhjx发布了新的文献求助10
7秒前
今天发布了新的文献求助10
7秒前
7秒前
思源的应助被寒冷的天亦采纳,获得10
7秒前
风与诗完成签到 ,获得积分10
7秒前
阳静发布了新的文献求助10
8秒前
白云黑土的应助被无限初丹采纳,获得10
8秒前
dawwf发布了新的文献求助10
8秒前
桐桐的应助被YUAN采纳,获得20
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8160467
求助须知:如何正确求助?哪些是违规求助? 9555463
关于积分的说明 21728123
捐赠科研通 7750270
什么是DOI,文献DOI怎么找? 3427393
关于科研通互助平台的介绍 2552425
邀请新用户注册赠送积分活动 2471741